Clinical trials: Neoplasia Prostate
Prostate Cancer
Safety and Efficacy of AGN-INM176 in Prostate Patients With Rising PSA
This Phase I/II open-label trial aims to evaluate the safety and efficacy of the herbal supplement INM176 in patients with a history of prostate cancer or low-risk disease under active surveillance.
- Trial name
- NCT06600698
- Testing
- INM176
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Milton S. Hershey Medical Center
Bladder Cancer
Nosocomial Infections During Total Prostatic Cystectomies (TPC) With Replacement Enterocystoplasty: Prophylactic Role of Urell®, Cranberry Fruit Juice Extract (Vaccicium Macrocarpon)
Total prostatic cystectomy with enterocystoplasty is the most extensive urological surgical procedure and one with the highest complication rate, especially infectious complication.
- Trial name
- Cranberry (NCT03986398)
- Testing
- Infection prophylaxis
- Where
- France
- Volunteers
- 10 people
- Sponsor
- Hopital Foch
Primary Prevention of Prostate Cancer
Prostate Cancer Prevention Trial With Quercetin and Genistein
The aim of the randomized controlled double-blind crossover trial is to evaluate the effectiveness of two dietary supplements containing polyphenolic phytochemicals (isoflavonoid genistein and flavonoid quercetin) in comparison…
- Trial name
- QUERGEN (NCT01538316)
- Testing
- Quercetin supplement, Genistein supplement
- Where
- 2 sites in Germany
- Volunteers
- 60 people
- Sponsor
- University of Hohenheim
Prostate Cancer
PRO-MERIT (Prostate Cancer Messenger RNA Immunotherapy)
Open-label, multicenter, dose titration and four-arm expansion trial to evaluate the safety, tolerability, immunogenicity, and preliminary efficacy of BNT112 cancer vaccine (BNT112) monotherapy or in combination with cemiplimab…
- Trial name
- PRO-MERIT (NCT04382898)
- Testing
- BNT112, Cemiplimab
- Where
- 22 sites in United States, Germany and 2 more
- Volunteers
- 75 people
- Sponsor
- BioNTech SE
Metastatic Castration-Resistant Prostate Cancer
PRECISE, a Study to Gather More Information About Bone Fractures and Survival in Castration-resistant PRostate Cancer (CRPC) patiEnts Treated With Radium-223 in Routine Clinical practIce in SwedEn
In this observational study researchers want to gather more information about bone fractures and survival in castration-resistant prostate cancer (CRPC) patients treated with radium-223 in routine clinical practice in Sweden.
- Trial name
- PRECISE (NCT04256993)
- Testing
- Radium-223 dichloride (Xofigo, BAY88-8223), Other standard care
- Where
- Sweden
- Volunteers
- 1,434 people
- Sponsor
- Bayer
Spina Bifida, Urothelial Neoplasm
Urothelium Tissue Engineering Using Biopsies From Transurethral Resection of Prostate
Different clinical conditions can require urinary bladder augmentation or replacement. Tissue engineered bladder has been clinically evaluated but is not recommended due to diverse side effects.
- Conditions
- Spina Bifida, Urothelial Neoplasm, Bladder, Neurogenic, Bladder Exstrophy
- Trial name
- IMOPU (NCT03698721)
- Testing
- Transurethral Resection of Prostate
- Volunteers
- 365 people
- Sponsor
- Central Hospital, Nancy, France
Prostate Cancer Metastatic, Prostate Cancer
Evaluation of Response to Abiraterone/Prednisone by Race/Ethnicity and Other Factors in Metastatic Hormone Naive Prostate Cancer
The investigators are conducting this study with men that have prostate cancer and are getting standard of care treatment with the drugs abiraterone acetate and prednisone.
- Trial name
- APRE (NCT03833921)
- Testing
- Abiraterone Acetate, Prednisone
- Where
- 3 sites in United States
- Volunteers
- 130 people
- Sponsor
- Martha Mims
Prostate Cancer
Response of Patients on Surveillance for Prostate Cancer to Dutasteride
Hypothesis: That, in men on surveillance for favorable risk prostate cancer treated with dutasteride, prostate specific antigen (PSA) kinetics is of value in identifying those men who harbor occult high grade prostate cancer.
- Trial name
- NCT01525914
- Testing
- Dutasteride
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- Sunnybrook Health Sciences Centre
Prostate Cancer Metastatic
Trial of ARV-110 in Patients With Metastatic Castration Resistant Prostate Cancer
Phase 1/2 dose escalation study to assess the safety and tolerability of ARV-110 in men with mCRPC who have progressed on prior approved systemic therapies for their castrate resistant disease (one of which must be enzalutamide…
- Trial name
- mCRPC (NCT03888612)
- Testing
- ARV-110
- Where
- 54 sites in United States
- Volunteers
- 248 people
- Sponsor
- Arvinas Inc.
Prostatic Adenocarcinoma
Dose Escalation Using Fiducial Markers in Image Guided Volumetric Modulated Arc Therapy to the Focal Lesion Micro Boost of Localized Prostate Cancer
Gold markers implanted in the prostate are used frequently for position verification of the prostate during external-beam radiotherapy.
- Trial name
- NCT03384199
- Testing
- Dose escalation to prostate focal lesion
- Where
- Egypt
- Volunteers
- 30 people
- Sponsor
- Kasr El Aini Hospital
Prostatic Neoplasms, Prostate Cancer
A Phase II Trial of Calcitriol and Naproxen in Patients With Recurrent Prostate Cancer
To determine whether, in this patient population, treatment with calcitriol and Naproxen is more effective in delaying the growth of prostate cancer than treatment with calcitriol alone as seen in historical controls.
- Trial name
- NCT00383487
- Testing
- Calcitriol, Naproxen-n-butyl nitrate
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Stanford University
Castration-Sensitive Prostate Adenocarcinoma, Metastatic Castration-Sensitive Prostate Adenocarcinoma
Estrogen to Improve Quality of Life for Men With Newly Diagnosed or Recurrent Metastatic Hormone Sensitive Prostate Cancer, EQUIP Trial
This phase II trial compares giving estrogen with an androgen receptor signaling inhibitor to standard of care luteinizing hormone-releasing hormone (LHRH) analogues with an androgen receptor signaling inhibitor for improving…
- Conditions
- Castration-Sensitive Prostate Adenocarcinoma, Metastatic Castration-Sensitive Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
- Trial name
- NCT07466498
- Testing
- Androgen Receptor Pathway Inhibitor, Transdermal Estrogen, Bone Scan
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Fred Hutchinson Cancer Center
Prostatic Neoplasm
Evaluation of SR 31747A Versus Placebo in Androgen-Independent Non Metastatic Prostate Cancer
To evaluate the efficacy of SR31747 given at 75 or 125mg per day versus placebo in androgen prostate cancer patient without distant metastases with Time to Clinical progression as main objective and PSA parameters, Tumor…
- Trial name
- ODYSSEY (NCT00174863)
- Testing
- SR31747A
- Where
- 13 sites in Australia, Belgium and 11 more
- Volunteers
- 232 people
- Sponsor
- Sanofi
Prostatic Neoplasms
Outpatient Radical Prostatectomy - Surgical and Anesthetic Considerations
Radical prostatectomy has become the gold standard treatment for prostate cancer. Regarding of morbidity of access on open retropubic radical prostatectomy a lot of centers around the world start to develop laparoscopic and…
- Trial name
- ORP-SAC (NCT01955863)
- Testing
- patient discharge on postoperative day 2, patient discharge on postoperative day 1, patient discharge in the day of surgery
- Where
- Brazil
- Volunteers
- 45 people
- Sponsor
- Wesley Justino Magnabosco
Prostate Cancer
Docetaxel, Radiation Therapy, and Prednisone in Treating Patients Who Have Undergone Surgery For Prostate Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel and prednisone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00348816
- Testing
- docetaxel, prednisone, Radical prostatectomy
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Prostate Cancer
Weekly Paclitaxel, Low-Dose Estramustine, and Carboplatin in the Treatment of Hormone Refractory Prostate Carcinoma
In this trial we will investigate how this three-drug regimen may be improved, both with respect to efficacy and toxicity, by making some modifications in the dosing and schedule in the treatment of patients with hormone…
- Trial name
- NCT00193193
- Testing
- Paclitaxel, Estramustine, Carboplatin
- Volunteers
- 100 people
- Sponsor
- SCRI Development Innovations, LLC
Breast Cancer, Cervical Cancer
Kukui Ahi Navigator Cancer Screening and Treatment Demonstration Project
This Cancer Prevention and Treatment Demonstration Project funded by the Centers of Medicare and Medicaid Services awarded six sites across the United States to develop Patient Navigator Programs to eliminate disparities in the…
- Conditions
- Breast Cancer, Cervical Cancer, Prostate Cancer, Colorectal Cancer
- Trial name
- NCT00379782
- Testing
- Navigation
- Where
- United States
- Volunteers
- 628 people, healthy volunteers welcome
- Sponsor
- Queen's Medical Center
Prostate Cancer Metastatic
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
This is a phase 3, randomized, open-label study of opevesostat compared to alternative abiraterone acetate or enzalutamide in participants with metastatic castration-resistant prostate cancer (mCRPC) with respect to overall…
- Trial name
- OMAHA-003 (NCT06136624)
- Testing
- Opevesostat, Abiraterone acetate, Enzalutamide
- Where
- 288 sites in United States, Argentina and 34 more
- Volunteers
- 1,310 people
- Sponsor
- Merck Sharp & Dohme LLC
Prostate, Cancer
Multivalent Conjugate Vaccine Trial for Patients With Biochem. Relapsed Prostate Cancer
This is a pilot trial designed to assess safety and immunogenicity of a multivalent conjugate vaccine for use in patients with biochemically relapsed prostate cancer.
- Trial name
- NCT00579423
- Testing
- QS21
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Memorial Sloan Kettering Cancer Center
Prostate Cancer
Continuous Monitoring of Prostate Position During Radiotherapy
This study is investigating measurement of prostate motion during radiotherapy using the implanted gold markers. If motion is greater than 3mm then the beam will be stopped and position corrected (gating).
- Trial name
- KIM Gating (NCT01742403)
- Testing
- R/T gating kV intrafraction monitoring
- Where
- Australia
- Volunteers
- 100 people
- Sponsor
- Royal North Shore Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.